Hydromethylthionine
drug drugOn this page
Also known as HidrometiltioninaLeucomethylene blueLeukomethylene blueMethylene blue leuco formMethylene blueleucoReduced methylene blueLeuco-methylthioniniumLeucomethylene blue (Mesylate)
Summary
Hydromethylthionine (CHEMBL549963) is a phase-3 clinical-stage small-molecule fluorochrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Chemistry: 285.4 Da · C16H19N3S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL549963 |
| Name | Hydromethylthionine |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 164695 |
| ChEBI | CHEBI:134180 |
| Molecular formula | C16H19N3S |
| Molecular weight | 285.4 |
| InChIKey | QTWZICCBKBYHDM-UHFFFAOYSA-N |
SMILES: CN(C)C1=CC2=C(C=C1)NC3=C(S2)C=C(C=C3)N(C)C
IUPAC name: 3-N,3-N,7-N,7-N-tetramethyl-10H-phenothiazine-3,7-diamine
ChEBI definition: A member of the class of phenothiazines that is 10H-phenothiazine in which the ring hydrogens at positions 3 and 7 have been replaced by dimethylamino groups.
Pharmacological roles (ChEBI): fluorochrome.
Other ChEBI roles (chemical / environmental): bacterial xenobiotic metabolite, rat metabolite, mouse metabolite.
Also known as: Hidrometiltionina, Hydromethylthionine, Leucomethylene blue, Leukomethylene blue, Methylene blue leuco form, Methylene blue, leuco, Reduced methylene blue, leucomethylene blue, HYDROMETHYLTHIONINE, Leuco-methylthioninium, Leucomethylene blue (Mesylate)
Parent form; salt/anhydrous children: CHEMBL4297221
Patent coverage: 544 distinct patent families (1,278 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 974 (76%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.